The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRNA | -37.99% | -75.7% | -24.62% | +20% |
| S&P | +11% | +85.61% | +13.15% | +151% |
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA).
The biotech's innovative qualities will come in handy.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.02B | -45.4% |
| Gross Profit | $757.00M | -41.6% |
| Gross Margin | 74.51% | 4.9% |
| Market Cap | $10.05B | -60.9% |
| Market Cap / Employee | $1.73M | 0.0% |
| Employees | 5.8K | 3.6% |
| Net Income | -$200.00M | -1638.5% |
| EBITDA | -$208.00M | -1055.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.13B | -31.1% |
| Accounts Receivable | $1.05B | -33.1% |
| Inventory | 332 | -19.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $686.00M | -47.4% |
| Short Term Debt | $48.00M | -5.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -22.31% | -9.7% |
| Return On Invested Capital | 6.96% | 1.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$880.00M | 48.7% |
| Operating Free Cash Flow | -$847.00M | 45.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.34 | 1.00 | 1.06 | 1.07 | -50.45% |
| Price to Sales | 4.95 | 3.44 | 3.48 | 4.51 | -14.14% |
| Price to Tangible Book Value | 1.35 | 1.01 | 1.07 | 1.08 | -50.30% |
| Enterprise Value to EBITDA | -8.20 | -5.65 | -7.43 | -30.30 | -97.42% |
| Return on Equity | -28.8% | -29.3% | -27.5% | -29.3% | 67.30% |
| Total Debt | $747.00M | $745.00M | $741.00M | $734.00M | -45.83% |
Microsoft CEO Satya Nadella talked about his company's doubling down on gaming, which should give gamers and investors pause.
Moderna has got some promising news on the coronavirus vaccine front.
Moderna shares got a boost as the company continued its COVID-19 vaccine trials.
Encouraging news coming out of the biotech regarding its coronavirus vaccine candidate caused its stock to pop.
MRNA earnings call for the period ending December 31, 2024.
MRNA earnings call for the period ending September 30, 2024.
MRNA earnings call for the period ending June 30, 2024.
MRNA earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
